Welcome to our dedicated page for OXFD news (Ticker: OXFD), a resource for investors and traders seeking the latest updates and insights on OXFD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OXFD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OXFD's position in the market.
On March 4, 2021, Oxford Immunotec Global PLC (Nasdaq: OXFD) announced the launch of its T-SPOT.COVID test, designed to qualitatively assess T cell immune responses to SARS-CoV-2. The test has received a CE mark and an EUA request has been filed with the FDA. Clinical studies show a high positive agreement of 96.6% with PCR results within 60 days of infection. The test complements antibody serology, enhancing the understanding of an individual's immune response. Furthermore, Oxford Immunotec is in the process of being acquired by PerkinElmer.
Oxford Immunotec Global PLC (Nasdaq: OXFD) has announced a partnership with GC MS and MESDIA Co., Ltd. to market the T-SPOT Discovery SARS-CoV-2 kit in South Korea. GC MS will handle marketing and sales, while MESDIA will manage imports, and Oxford Immunotec Korea will provide support. This kit is intended for research use and assesses T cell responses to SARS-CoV-2, which may offer additional insights into COVID-19 immunity beyond antibody detection. The kit is currently used in studies for vaccine development in the UK.
Oxford Immunotec Global PLC (OXFD) has updated its T-SPOT Discovery SARS-CoV-2 kit for research use only. The new configuration focuses on antigens that enhance T cell responses specific to SARS-CoV-2, including a panel for endemic coronaviruses to study their immune response interplay. This advancement stems from ongoing research, highlighting the potential protective effect of previous HCoV exposure on SARS-CoV-2 infection. Dr. Magdalena Dudek emphasized the kit’s enhanced capability to provide insights into T cell responses.
Oxford Immunotec Global PLC (OXFD) launched a monthly survey, 100 Physicians Find, gathering insights from 100 medical professionals on COVID-19 management. The inaugural findings reveal that 82% of respondents trust molecular (PCR) tests, while only 56% express confidence in serology tests. Notably, 75% of physicians reported unmet diagnostic needs, highlighting a demand for new testing alternatives. CEO Dr. Peter Wrighton-Smith stated that these insights will guide future diagnostic developments, ensuring that medical professionals' requirements are addressed during the pandemic.
Oxford Immunotec Global PLC (Nasdaq: OXFD) has initiated a collaboration with Valneva to conduct T cell testing in the VLA2001-201 Phase I/II clinical study, which evaluates a COVID-19 vaccine candidate. This study will assess the vaccine's safety, tolerability, and immunogenicity in healthy adults. Utilizing the T-SPOT Discovery SARS-CoV-2 test, Oxford aims to measure T cell responses induced by the vaccine, potentially providing critical efficacy insights. The collaboration highlights Oxford's expertise in T cell measurement through its established technology platform.
PerkinElmer will acquire Oxford Immunotec for $22.00 per share, valuing the deal at approximately $591 million. This acquisition, expected to close by mid-2021, represents a premium of 28.3% compared to Oxford Immunotec's last closing price and significantly enhances PerkinElmer's portfolio in infectious disease testing, particularly for tuberculosis. PerkinElmer anticipates the deal to be modestly accretive to earnings in the first year and expects Oxford Immunotec's sales growth to outpace its own Diagnostics franchise. Oxford Immunotec will become a privately held company post-acquisition.
Oxford Immunotec Global PLC (Nasdaq: OXFD) has launched the Global T cell expert consortium (GTEC), aimed at advancing T cell research, particularly in relation to COVID-19. The GTEC brings together leading experts to enhance education and research on T cells, an essential component of immunity. The consortium's goals include advocating for T cell measurement, promoting education on immunity, and facilitating innovative research studies. The initiative is supported by Oxford Immunotec, enhancing its role in the global public health landscape.
Oxford Immunotec Global PLC (Nasdaq: OXFD) has received approval from South Korea's Ministry of Food and Drug Safety for its T-Cell Select reagent kit. This kit simplifies the T-SPOT.TB test process by automating cell preparation from blood samples, reducing labor costs and improving laboratory integration. It allows for sample storage at room temperature for up to 54 hours, enhancing workflow flexibility. CEO Peter Wrighton-Smith highlighted that this approval will facilitate wider adoption of the T-SPOT.TB test in South Korea, benefiting more patients.
Oxford Immunotec Global PLC (Nasdaq: OXFD) has signed an exclusive distribution agreement with RIKEN Genesis Co., Ltd in Japan for its T-SPOT Discovery SARS-CoV-2 kit, designed to detect SARS-CoV-2 specific T cells. This kit, already available in Europe and the USA, aims to enhance understanding of immunity against COVID-19. The collaboration seeks to broaden the usage of this research-use-only kit in Japan, contributing to the ongoing pandemic management. Oxford Immunotec emphasizes the potential for new insights into T cell immunity to COVID-19 through this partnership.
Oxford Immunotec Global PLC (Nasdaq:OXFD) has announced a virtual investor event scheduled for December 17, 2020. CEO Dr. Peter Wrighton-Smith and CFO Matt McLaughlin will discuss key topics such as the TB market's growth opportunities, the Company’s automation strategies, and plans regarding SARS-CoV-2 testing. The conference call will be available via telephone and webcast, with an emphasis on the Company’s ongoing initiatives and future vision in diagnostics.
